Shares in Novo Nordisk (NYSE:NVO) fell today after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results. The Denmark-based company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the […]
Featured
Baxter posts Street-beating Q4 earnings, sales
Shares in Baxter (NYSE:BAX) fell slightly this morning after the company topped expectations on Wall Street with its fourth quarter and full-year results. The Deerfield, Ill.-based company swung to a loss in Q4 thanks to a $322 million hit from the recently-enacted U.S. tax reform legislation. Baxter posted -$71 million in net losses for the quarter […]
Teva closes $703m sale of global women’s health biz to CVC Capital
Teva Pharmaceuticals (NYSE:TEVA) has finished the $703 million sale of a portfolio of products in its global women’s health business to CVC Capital Partners. The portfolio of divested products includes fertility medicines like Ovaleap, oral contraceptives like Zoely and osteoporosis drugs like Actonel. Now that the sale is closed, the portfolio of medicines will be sold under […]
Antidote looks to leverage AI, travel e-commerce tech to improve clinical trial enrollment
Clinical trial artificial intelligence company Antidote is looking to improve access to and enrollment in clinical trials using technology from the e-commerce world, according to a Wired report. Former travel and airline fare aggregator Kayak VP Pablo Graiver is heading the operation, which streamlines access to clinical trials for patients seeking them out. Read the […]
Nemaura Medical touts clinical trial data for non-invasive glucose monitor
Shares in Nemaura Medical (NSDQ:NMRD) jumped today after the company touted positive data from the European clinical trial program for its non-invasive sugarBeat glucose monitoring system. The summary results were taken from a 25-patient group in the three-stage trial, made up of 80% Type I diabetics and 20% Type II diabetics. Each patient continuously wore the […]
Arkray inks licensing deal with Mellitus Health for insulin titration software
Arkray‘s U.S. business has inked a licensing deal with Mellitus Health for its insulin titration software, Insulin Insights. Mellitus Health, formerly known as Insulin Algorithms, developed the clinical decision-support tool to help doctors keep their patients’ blood sugar levels in control with optimized insulin therapy. The software is compatible with any blood glucose monitoring system […]
Eli Lilly beats the Street with Q4 earnings
Shares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results. The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for […]
Boston Scientific’s drug-coated balloon goes up against Medtronic’s DCB in first-of-its-kind trial
Top-line results from a head-to-head trial comparing Boston Scientific‘s (NYSE:BSX) Ranger drug-coated balloon and Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB found no statistically significant difference in patency rates between the two drug-device products. The trial is the first of its kind, according to Boston Scientific’s president of peripheral interventions, Jeff Mirviss. “As a leader in the […]
Dexcom takes on Abbott in head-to-head glucose monitoring trial
Updated to include a statement from Abbott. Dexcom (NSDQ:DXCM) touted data today from a head-to-head trial comparing its G5 mobile continuous glucose monitoring system with Abbott‘s (NYSE:ABT) recently-approved FreeStyle Libre Flash glucose monitoring system. The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by […]
Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies
The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the […]